



## Cogent Biosciences Announces Participation at Upcoming Investor Conferences

February 1, 2023

WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- [Cogent Biosciences, Inc.](https://www.cogentbio.com) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will participate in the following upcoming investor conferences in February:

- **Guggenheim Healthcare Talks Idea Forum Oncology Day**  
Date/Time: Wednesday, February 8, 2023 at 10:10 a.m. ET
- **SVB Securities Global Biopharma Conference:**  
Date/Time: Tuesday, February 14, 2023 at 9:20 a.m. ET

A live webcast of each event can be accessed on the Investors & Media page of Cogent's website at <https://investors.cogentbio.com/events>. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days.

### About Cogent Biosciences, Inc.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at [www.cogentbio.com](http://www.cogentbio.com). Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

### Contact:

Christi Waarich  
Senior Director, Investor Relations  
[christi.waarich@cogentbio.com](mailto:christi.waarich@cogentbio.com)  
617-830-1653